Pieris Pharma (PIRS) - Long-Term Debt to Capital Coefficient

Pieris Pharmaceuticals (PIRS) develops advanced protein-based cancer therapies using a versatile platform to deliver a range of licensable products. Its international operations in respiratory and oncological pathologies are protected by humanitarian status, which eliminates the impact of sanctions. The business relies on proprietary Anticalin patents, binding partners through long-term contracts. The asset value of 0.09 as tracked on this chart confirms the current trend.

Defensive assets are selected based on the criterion of minimal debt load. Pieris Pharmaceuticals (PIRS) maintains this standard by investing in a high-paid staff of elite biologists to develop protein therapies. The metric compares liabilities with a maturity of over one year against total equity. By analyzing the ratio of long-term loans to equity, an investor assesses the company's financial stability. A decrease in this coefficient may indicate either debt repayment or a temporary increase in capitalization.